Thank You for Signing Up!

We’re thrilled to welcome you as an email subscriber. Your support helps advance scholarly research and ensures access to cutting-edge psychiatry articles and insights.

Personalize Your Experience

Help us customize your content and recommendations by verifying your professional credentials with your National Provider Identifier (NPI).

Note: You’ll need to log in or create an account to save your NPI information.

Do you have an NPI number?

Choose your interests

Select topics that interest you to receive personalized recommendations and content.

Our Recently Published Articles

JCP
Rethinking Amisulpride: Could N-Methylation Result in a New and Even Better Antipsychotic?
ASCP Corner

January 26, 2026

This article will familiarize US clinicians with amisulpride’s history and data, and the rationale behind development of LB-102, an N-methylated analogue of amisulpride.
,
JCP
Urological Commentary on Ketamine-Associated Uropathy
Letter to the Editor

January 26, 2026

The author comments on a recent article reviewing ketamine-associated uropathy in therapeutic and nontherapeutic settings.
JCP
Ketamine-Associated Uropathy in Therapeutic Contexts: Reply to Abdelrahman
Letter to the Editor

January 26, 2026

Dr Andrade responds to a letter commenting on his recent review of ketamine-associated uropathy in therapeutic and nontherapeutic settings.
PCC
Basal Ganglia Stroke With Lower Motor Neuron Features
Case Report

January 22, 2026

A 60-year-old man exhibited left-sided toe walking and right-sided weakness despite previous history of left sided basal ganglia stroke, challenging the notion that adult toe walking is a hallmark…
, , , et al
PCC
Benign Ethnic Neutropenia and Clozapine
Case Report

January 22, 2026

This case highlights the importance of recognizing benign ethnic neutropenia to prevent unnecessary clozapine discontinuation.
, , , et al
JCP
Next-Step Treatment Options for Treatment-Resistant Depression
Consensus Statement

January 21, 2026

Strong consensus emerged for augmentation with second-generation antipsychotics, TMS, and ketamine/esketamine in the base vignette. Preferences shifted to include non-augmentative antidepressants and ECT based on patient characteristics.
, , , et al
JCP
SSRI Discontinuation and AUD Relapse
Case Report

August 26, 2024

A man with AUD achieves sobriety on treatment with an SSRI and naltrexone, but then stops taking the SSRI to participate in a psilocybin “ceremony.” What factors contributed to…
, , , et al
JCP
Olanzapine and Mirtazapine for Cancer-Related Anorexia
Clinical and Practical Psychopharmacology

August 21, 2024

Dr Andrade discusses two RCTs that investigated the utility of olanzapine and mirtazapine in addressing appetite loss in cancer patients.
JCP
Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine
Commentary

August 21, 2024

Dr Rosenbaum comments on the challenge of evaluating trials of treatments whose effects are unmistakable, and how this dilemma may be addressed.

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe